The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and
immunogenicity of certolizumab pegol treatment in pediatric subjects, aged 6 to 17, with
moderately to severely active Crohn's disease. The target enrollment is 160 subjects.